Clinical trials: Controlled Hypertension
Glaucoma, Cataract
Ologen (OculusGen)-Phacotrabeculectomy Historical Control Study in India
1. . Study Objective: The objective of this study is to determine the safety and effectiveness of the OculusGenTM Biodegradable Collagen Matrix Implant in phacotrabeculectomy surgery.
- Trial name
- NCT00477685
- Testing
- OculusGen Biodegradable Collagen Matrix Implant
- Where
- India
- Volunteers
- 10 people
- Sponsor
- Pro Top & Mediking Company Limited
Hypertension, High Blood Pressure
To Demonstrate Non-inferiority of Combination of 5 mg Amlodipine/ 80 mg Valsartan to 160 mg Valsartan Alone
The purpose of the study was to assess efficacy and safety of fixed dose combination of 5 mg amlodipine/80 mg valsartan compared to 160 mg valsartan monotherapy in lowering blood pressure in Taiwanese patients.
- Trial name
- NCT01070043
- Testing
- Amlodipine 5mg/Valsartan 80 mg, Valsartan
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Novartis
Essential Hypertension
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension
This study assessed the efficacy of LCZ696 in Japanese patients with essential hypertension
- Trial name
- NCT01599104
- Testing
- LCZ696, Olmesartan
- Where
- 61 sites in Japan
- Volunteers
- 1,161 people
- Sponsor
- Novartis Pharmaceuticals
Liver Cirrhosis
A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients
To evaluate the safety of IV conivaptan in stable euvolemic or hypervolemic cirrhotic patients, and to characterize the effects of IV conivaptan on the hepatic hemodynamic response in patients with cirrhosis.
- Trial name
- NCT00592475
- Testing
- conivaptan
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Cumberland Pharmaceuticals
Open Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
The study is intended to test the effectiveness and safety of Netarsudil / Latanoprost 0.02% / 0.005% Ophthalmic Solution, relative to GANFORT® for lowering of intraocular pressure (IOP) in patients with elevated intraocular…
- Trial name
- NCT03284853
- Testing
- Netarsudil/Latanoprost 0.02%/0.005%, GANFORT®
- Where
- 68 sites in Austria, Belgium and 9 more
- Volunteers
- 436 people
- Sponsor
- Aerie Pharmaceuticals
Pulmonary Arterial Hypertension
FK506 (Tacrolimus) in Pulmonary Arterial Hypertension
Mutations in bone morphogenetic protein receptor 2 (BMPR2) are present in >80% of familial and ~20% of sporadic pulmonary arterial hypertension (PAH) patients.
- Trial name
- TransformPAH (NCT01647945)
- Testing
- FK506 level < 2 ng/ml, FK506 level 2-3 ng/ml, FK506 level 3-5 ng/ml
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Edda Spiekerkoetter
Atherosclerosis, Cardiovascular Diseases
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and…
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension
- Trial name
- ACCORD (NCT00000620)
- Testing
- Anti-hyperglycemic Agents, Anti-hypertensive Agents
- Where
- 7 sites in United States, Canada
- Volunteers
- 10,251 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Stroke, Acute Ischemic, Hypertension
TEAMS-BP (The Enhancement of Social Networks to Augment Management of Stroke-Blood Pressure)
This study aims to compare the efficacy of a social network intervention versus individual hypertension counseling to improve blood pressure control after stroke.
- Trial name
- TEAMS-BP (NCT05258890)
- Testing
- Social Network Group Counseling, Individual Counseling
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Brigham and Women's Hospital
Pulmonary Hypertension
Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction
Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of subjects with combined pre- and post-capillary pulmonary hypertension (CpcPH) due to left ventricular dysfunction.
- Trial name
- MELODY-1 (NCT02070991)
- Testing
- Macitentan
- Where
- 32 sites in United States, Austria and 9 more
- Volunteers
- 63 people
- Sponsor
- Actelion
Hypertension
Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension
Liquid potassium-magnesium citrate (KMgCit) as a pharmaceutical formulation will lower blood pressure among patients with pre- or Stage I hypertension on their customary diet.
- Trial name
- NCT01682837
- Testing
- Potassium chloride powder, Potassium citrate powder, Potassium magnesium citrate powder
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Texas Southwestern Medical Center
Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma
Safety and tolerability of three different concentrations (0.1%, 03%, 0.6%) of the investigational SHP639 eye drops will be evaluated in participants with high eye pressure or primary open-angle glaucoma.
- Trial name
- NCT03131167
- Testing
- SHP639 (n=60)
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Shire
Glaucoma, Open-Angle, Ocular Hypertension
To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
To compare the efficacy and safety of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.
- Trial name
- NCT04944290
- Testing
- Brinzolamide/brimonidine ophthalmic suspension, Simbrinza 0.2%/1% Ophthalmic Suspension
- Where
- United States
- Volunteers
- 447 people
- Sponsor
- Padagis LLC
Ocular Hypertension, Open-angle Glaucoma
Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
To evaluate the ocular hypotensive efficacy and ocular and systemic safety of AR-13324 Ophthalmic Solution, 0.02% compared to the active comparator Timolol maleate Ophthalmic Solution, 0.5%
- Trial name
- Rocket-1 (NCT02207491)
- Testing
- Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%
- Where
- United States
- Volunteers
- 411 people
- Sponsor
- Aerie Pharmaceuticals
Pulmonary Arterial Hypertension
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)
The objectives of this study are to evaluate the efficacy and safety of sotatercept (MK-7962) treatment (plus background pulmonary arterial hypertension (PAH) therapy) versus placebo (plus background PAH therapy) at 24 weeks in…
- Trial name
- NCT04576988
- Testing
- Sotatercept, Background PAH Therapy
- Where
- 120 sites in United States, Argentina and 19 more
- Volunteers
- 324 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Acute Coronary Syndrome
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death…
- Trial name
- AEGIS-II (NCT03473223)
- Testing
- Apolipoprotein A-I [human] (apoA-I)
- Where
- 903 sites in United States, Argentina and 47 more
- Volunteers
- 18,226 people
- Sponsor
- CSL Behring
Glaucoma
Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes
This is a randomized, double blind, two-arm, parallel group, active controlled bioequivalence study, at multiple clinical trial sites designed to demonstrate bioequivalence of Brinzolamide 1% ophthalmic suspension (manufactured…
- Trial name
- NCT02512042
- Testing
- Test-Brinzolamide 1% Ophthalmic suspension, Reference-Brinzolamide 1% Ophthalmic suspension
- Where
- 10 sites in United States
- Volunteers
- 973 people
- Sponsor
- Actavis Inc.
Pulmonary Arterial Hypertension
A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)
This local Phase 3 study is planned to confirm the efficacy and safety in Japanese PAH participants. The primary population of this study is Japanese PAH participants with World Health Organization Functional Class (WHO FC) II or…
- Trial name
- NCT05818137
- Testing
- Sotatercept
- Where
- 17 sites in Japan
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Ischemic Stroke
China Antihypertensive Trial in Acute Ischemic Stroke
This randomized trial tests the effect of early blood pressure reduction on major disability and death among patients with acute ischemic stroke in china.
- Trial name
- CATIS (NCT01840072)
- Testing
- Active antihypertensive treatment
- Where
- China
- Volunteers
- 4,071 people
- Sponsor
- Tulane University
Uncontrolled Hypertension
A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension
The main purpose of this study is to assess the serum free cortisol response after ACTH stimulation test at baseline and at Week 8 in participants with uncontrolled hypertension.
- Trial name
- NCT06336356
- Testing
- Baxdrostat
- Where
- 10 sites in United States
- Volunteers
- 48 people
- Sponsor
- AstraZeneca
Open-angle Glaucoma, Ocular Hypertension
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
To evaluate ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution.
- Trial name
- NCT02558374
- Testing
- AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID
- Where
- United States
- Volunteers
- 708 people
- Sponsor
- Aerie Pharmaceuticals